Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word “Rare” in Rare Cancers

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407–18. https://doi.org/10.1038/s41568-018-0007-6.

    Article  CAS  PubMed  Google Scholar 

  2. Votanopoulos KI, et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann Surg Oncol. 2020;27:1956–67. https://doi.org/10.1245/s10434-019-08143-8.

    Article  PubMed  Google Scholar 

  3. Sato T, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;2009(459):262–5. https://doi.org/10.1038/nature07935.

    Article  CAS  Google Scholar 

  4. Votanopoulos KI, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26:139–47. https://doi.org/10.1245/s10434-018-7008-2.

    Article  PubMed  Google Scholar 

  5. Forsythe SD, et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study. Clin Cancer Res. 2021;27:5141–50. https://doi.org/10.1158/1078-0432.CCR-21-0982.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Forsythe S, et al. Patient specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12086-y.

Download references

Author information

Authors and Affiliations

  1. Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven D. Forsythe MS, Hemamylammal Sivakumar MS, Richard A. Erali MD, MPH, Aleksander Skardal PhD & Konstantinos I. Votanopoulos MD, PhD

  2. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven D. Forsythe MS, Aleksander Skardal PhD & Konstantinos I. Votanopoulos MD, PhD

  3. Wake Forest Organoid Research Center (WFORCE), Winston-Salem, USA

    Steven D. Forsythe MS, Richard A. Erali MD, MPH & Konstantinos I. Votanopoulos MD, PhD

  4. Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA

    Hemamylammal Sivakumar MS & Aleksander Skardal PhD

  5. Department of Surgery, Division of Surgical Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA

    Richard A. Erali MD, MPH & Konstantinos I. Votanopoulos MD, PhD

  6. Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Richard A. Erali MD, MPH & Konstantinos I. Votanopoulos MD, PhD

  7. The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA

    Aleksander Skardal PhD

Authors
  1. Steven D. Forsythe MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hemamylammal Sivakumar MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard A. Erali MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aleksander Skardal PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konstantinos I. Votanopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos I. Votanopoulos MD, PhD.

Ethics declarations

Disclosure

AS—inventor on patents describing the tumor organoid technology employed in this work. KV—Organoid technology patents currently not licensed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forsythe, S.D., Sivakumar, H., Erali, R.A. et al. ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word “Rare” in Rare Cancers. Ann Surg Oncol 29, 7368–7369 (2022). https://doi.org/10.1245/s10434-022-12089-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12089-9

Search

Navigation